7737-17-9
7737-17-9
Chemical Structure
Aminoacetone hydrochloride
- CAS No.: 7737-17-9
- Formula:C3H8ClNO
- Molecular Weight:109.55
IUPAC Name: 1-aminopropan-2-one hydrochloride
InChIKey: RUCLDQBBIJKQHO-UHFFFAOYSA-N
SMILES: CC(CN)=O.Cl
Biological Activity: Aminoacetone hydrochloride is an α-aminoketone and also a catabolite of threonine and glycine. When accumulated under pathological conditions, Aminoacetone hydrochloride participates in oxidative damage and protein dysfunction via the production of reactive oxygen species (ROS) and methylglyoxal, and it is associated with phenotypes such as diabetes, mitochondrial damage and sleep disorders[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Aminoacetone hydrochloride | 99.44% | Aminoacetone hydrochloride is an α-aminoketone and also a catabolite of threonine and glycine. When accumulated under pathological conditions, Aminoacetone hydrochloride participates in oxidative damage and protein dysfunction via the production of reactive oxygen species (ROS) and methylglyoxal, and it is associated with phenotypes such as diabetes, mitochondrial damage and sleep disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycine | 99.93% | Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine inhibits the membrane aggregation of NINJ1 and prevents plasma membrane rupture during cell death. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycine-15N | 99.95% | Glycine-15N is the 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycine-2-13C | 99.78% | Glycine-2-13C is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycine-13C2 | 99.88% | Glycine-13C2 is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycine-1-13C | 99.94% | Glycine-1-13C is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycine-1-13C,15N | 99.5% | Glycine-1-13C,15N is the 13C- and 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycine-13C2,15N | 99.92% | Glycine-13C2,15N is the 13C- and 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycine-2-13C,15N | 98.0% | Glycine-2-13C,15N is the 13C- and 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-Aminoacetamide hydrochloride | 99.83% | 2-Aminoacetamide hydrochloride (Glycinamide hydrochloride) is a derivative of Glycine (HY-Y0966). 2-Aminoacetamide hydrochloride forms cell-absorbable nanocomplexes with proteins (such as bovine serum albumin) through strong electrostatic interactions, promoting cellular uptake of related proteins. 2-Aminoacetamide hydrochloride synergizes with BMP2 to upregulate the expression of osteogenic marker genes (such as Col1a1, Alp, Runx2) and proteins (such as COL1, BSP), enhancing collagen synthesis. 2-Aminoacetamide hydrochloride synergizes with BMP2 to promote osteoblast differentiation in vitro and bone regeneration in vivo. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Hydroxyacetone | 98.93% | Hydroxyacetone is a toxic compound. Hydroxyacetone can be isolated from e-cigarette aerosols. Hydroxyacetone reduces the activity of cellular Mitochondrial reductase (with an IC50 of 5.53 mg/mL for mitochondrial reductase in BEAS-2B cells) and increases ROS levels. Hydroxyacetone induces mitochondrial stress and oxidative damage. Hydroxyacetone induces destabilization of F-actin. At high concentrations, Hydroxyacetone promotes cell rounding and Apoptotic body formation. Hydroxyacetone exerts toxic effects on cells including airway epithelial cells and possesses respiratory toxicity potential.\n |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhou S, et al. Aminoacetone is associated with sleep latency. Sleep Med. 2025;128:183-186. [Content Brief]
- [2]. Dutra F, et al. Aminoacetone induces iron-mediated oxidative damage to isolated rat liver mitochondria. Arch Biochem Biophys. 2004;430(2):284-289. [Content Brief]
- [3]. Ramos LD, et al. Aerobic co-oxidation of hemoglobin and aminoacetone, a putative source of methylglyoxal. Free Radic Biol Med. 2021;166:178-186. [Content Brief]
